Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

Stem cell therapy for regenerating intervertebral discs - 16/07/2020

Ulm’s simulator has Europe’s back

Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

Innovations in the field of endoscopy - 08/06/2020

Gastroscopies with pill cameras

A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Novel coronavirus outbreak - a status report on recent developments - 04/03/2020

Waiting for a SARS-CoV-2 vaccine

Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

Article - 23/04/2019

How can care infrastructures benefit from digitization?

The pilot project NeCTra (Networking - Care - Transparency) investigates how care processes within an urban social environment can be improved by using digital technologies. The goal is to bring together all partners and institutions in real time so that people in need of care and those seeking advice receive appropriate support more quickly.

Expert interview on NTDs – part 1 - 11/04/2019

Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

Article - 03/04/2019

HKK Bionics empowers hand gripping functions

A spin-off from the Ulm University of Applied Sciences is aiming to provide people whose hands have been paralysed due to accident or illness with a new kind of orthopaedic aid. Dominik Hepp and Tobias Knobloch are currently starting serial production of a hand orthosis prototype. The two medical engineers from Ulm, who founded HKK Bionics GmbH in 2017, plan to commence final tests in 2019.

Article - 18/03/2019

EHR and PHR: digital records in the German healthcare system

EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.

Article - 24/01/2019

Scientists to combat antibiotic-resistant bacteria in wastewater

In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

Article - 10/01/2019

Stocktaking and recommendations for action: the BBAW’s fourth gene technology report

In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…

Dossier - 28/08/2018

With molecular diagnostics to biomarker-based personalised therapy

Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

Dossier - 14/06/2016

CRISPR/Cas – genome editing is becoming increasingly popular

The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

Dossier - 18/04/2016

Epigenetics – heritable traits without changing the DNA sequence

Epigenetics, i.e. the inheritance of traits that does not involve a change in the DNA sequence, was once a controversial subject that has since become a central focus of biological research. Epigenetic inheritance is now studied by numerous national and international research programmes. Many cellular regulatory and differentiation processes are controlled by epigenetic mechanisms that take place on different levels.

Dossier - 02/12/2013

RNA interference confidence is returning

The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

Dossier - 15/10/2013

Adult stem cells hope for regenerative therapies

Adult stem cells have the lifelong ability to generate new specialised cells. They secure the continuous replenishment of cells therefore enabling the constant replacement of dying cells with new ones. Progress in the characterisation isolation and specific differentiation of adult stem cells over recent years raises hopes for the future use of the cells in the therapy of degenerative diseases. Knowledge about adult stem cells also has the…

Dossier - 21/05/2013

No new drugs to be placed on the market without clinical trials

New pharmaceuticals are subject to approval by drug authorities. Here clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the drug. The costs including failures can amount to approximately one billion US dollars per drug.

Dossier - 08/10/2012

Marine biotechnology unknown sources of hope from the depths of the sea

Biotechnological methods are used to investigate marine life and the results obtained from these investigations advance research in the fields of medicine and energy and into substances used as food supplements and cosmetics. The area of marine biotechnology is fairly diverse. Although it is not on the coast even the southern German state of Baden-Württemberg is involved in marine biotechnology.

Dossier - 01/10/2012

Systems biology understanding complex biological systems

Systems biology studies complex interactions within biological systems on the genome proteome and organelle level. Many techniques from the fields of systems theory and associated fields can be used to gain an understanding of the behaviour and biological mechanisms of cellular systems.

Dossier - 10/09/2012

Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe

In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…